Literature DB >> 8545484

Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715).

R T Layer1, P Popik, T Olds, P Skolnick.   

Abstract

Functional N-methyl-D-aspartate (NMDA) antagonists including competitive antagonists, glycine partial agonists, and use-dependent channel blockers exhibit antidepressant-like actions in preclinical models. The present study examined the effects of eliprodil (SL-82.0715), an NMDA antagonist acting at polyamine sites, in behavioral and neurochemical tests predictive of antidepressant activity. In mice, eliprodil produced a dose-dependent reduction in immobility in the forced swim test, but was inactive in the tail suspension test. Chronic treatment with eliprodil produced both a significant downregulation of beta-adrenoceptors and a reduction in the potency of glycine to inhibit [3H]5,7-dichlorokynurenic acid binding to strychnine-insensitive glycine receptors in neocortical membranes. In toto, these data indicate that like other NMDA antagonists, eliprodil possesses antidepressant-like actions in preclinical tests predictive of clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8545484     DOI: 10.1016/0091-3057(95)00155-p

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  32 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 3.  Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models.

Authors:  Gislaine Zilli Réus; Airam Barbosa de Moura; Laura Araújo Borba; Helena Mendes Abelaira; João Quevedo
Journal:  Mol Neuropsychiatry       Date:  2019-05-21

Review 4.  The impact of sex as a biological variable in the search for novel antidepressants.

Authors:  Alexia V Williams; Brian C Trainor
Journal:  Front Neuroendocrinol       Date:  2018-05-31       Impact factor: 8.606

5.  Lack of persistent effects of ketamine in rodent models of depression.

Authors:  Piotr Popik; Tomasz Kos; Magdalena Sowa-Kućma; Gabriel Nowak
Journal:  Psychopharmacology (Berl)       Date:  2008-05-07       Impact factor: 4.530

6.  A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.

Authors:  Nancy Diazgranados; Lobna Ibrahim; Nancy E Brutsche; Andrew Newberg; Phillip Kronstein; Sami Khalife; William A Kammerer; Zenaide Quezado; David A Luckenbaugh; Giacomo Salvadore; Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Arch Gen Psychiatry       Date:  2010-08

7.  Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression.

Authors:  Beata Karolewicz; Craig A Stockmeier; Gregory A Ordway
Journal:  Neuropsychopharmacology       Date:  2005-08       Impact factor: 7.853

8.  NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test.

Authors:  Mehdi Ghasemi; Laleh Montaser-Kouhsari; Hamed Shafaroodi; Behtash Ghazi Nezami; Farzad Ebrahimi; Ahmad Reza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2009-07-16       Impact factor: 4.530

9.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

Review 10.  Advances in the treatment of anxiety: targeting glutamate.

Authors:  Asher B Simon; Jack M Gorman
Journal:  NeuroRx       Date:  2006-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.